en · de · es · fr · pt
melanotan-2-notes.peptides9002.com › Faq › Melanotan Ii Background And Mechanism — Research Overview

Melanotan Ii Background And Mechanism — Research Overview

By Editorial Desk · published 2025-09-24 · last reviewed 2025-10-20 · Faq

The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.

Melanotan II Background and Mechanism

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideMelanocortin receptor agonist
Molecular formulaC50H69N15O9Neutral form, mass near 1024.2 g/mol
Primary targetsMC1R, MC3R, MC4R, MC5RBinding is non-selective across subtypes
Related compoundsAlpha-MSH, melanotan I, afamelanotideStructurally or functionally related peptides
Common abbreviationsMT-II, MT-2Naming in the literature is not uniform

Peptide Identity and Structural Background

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Related pages on this site

Reference notes

=== Fluorescence resonance energy transfer === Fluorescence Resonance Energy Transfer (FRET) utilizes energy transferred between the donor and the acceptor molecules that are in close proximity. FRET uses a fluorescently labeled ligand, as with FP. Energy transfer within FRET begins by exciting the donor. The dipole–dipole interaction between the donor and the acceptor molecule transfers the energy from the donor to the acceptor molecule. If the ligand is bound to the receptor-antibody complex, then the acceptor will emit light. When using FRET, it is critical that there is a distance smaller than 10 nm between the acceptor and donor, in addition to an overlapping absorption spectrum between acceptor and donor, and that the antibody does not interfere or block the ligand binding site.

In two July polls, he was polling at 6.4% and at 3.1%. In early August, Noboa was polling at 2.5% and 3.7%. In a poll conducted a week before the election, he was polling at 3.3%. On 20 August, Noboa gathered 23.47% of the actual votes and advanced to the run-off election set for 15 October, facing Luisa González. His second-place finish was seen as surprising, with some attributing his rise in popularity to his debate performance. Noboa credited the young voter base for his victory. In the second round, Noboa was elected, winning 55% of the vote. Elected at age 35, he is the youngest president in Ecuadorian history, beating the record of Jaime Roldós Aguilera who was inaugurated at 38 years old in 1979. Following his victory, Noboa thanked voters for believing in "a new political project, a young political project, an improbable political project". He vowed "to return peace to the country, to give education to the youth again, to be able to provide employment to the many people who are looking for it". Prior to taking office, Noboa travelled to the United States and Europe to search for investors and business lenders to assist the country's debt crisis. During his visit to Washington, D.C. he met with officials from the World Bank, the International Monetary Fund, and the Organization of American States. On 17 October, Noboa visited the Presidential Palace to meet with outgoing President Guillermo Lasso.

Anderson University* Master of Medical Science (MMS), Pathologists’ Assistant Studies Carroll University** Master of Science in Pathologists' Assistant Studies Drexel University* Master of Science in Pathologists’ Assistant Studies Duke University* Master of Health Science Loma Linda University* Master’s Degree in Health Science, Pathologists’ Assistant Medical University of South Carolina*** Master of Science in Pathologists' Assistant Studies Program Old Dominion University EVMS* Master of Health Sciences, Pathologists’ Assistant Quinnipiac University* Master of Health Science Rosalind Franklin University* Master of Science in Pathologists' Assistant Studies Touro University* Master of Science Tulane University* Master of Science in Anatomic Pathology University of Alberta* MSc with Specialization in Pathologists' Assistant University of Calgary* Master of Pathologists' Assistant University of Jamestown*** Master of Health Science University of Maryland Baltimore* Master of Science in Pathology University of Tennessee Health Science Center* Master's of Health Science (MHS) in Pathologists' Assistants University of Texas Medical Branch at Galveston* Master of Pathologists’ Assistant University of Toledo* Master of Science in Biomedical Science University of Toronto* Master of Health Science Degree in Laboratory Medicine - Pathologists’ Assistant Field University of Washington*** Master of Science in Anatomic Pathology University of Western Ontario* Master of Clinical Science in Pathologists' Assistant Studies Wayne State University* Master of Science in Pathologists' Assistant Studies West Virginia University* Master of Health Science As of 2/20/2026, the programs above have the following status with the National Accrediting Agency for Clinical Laboratory Sciences: |*| Accredited |**| Serious Applicant Status |***| Submitted documentation to become accredited

Sources: en.wikipedia.org

Notes from published material

=== RA 27/3 === Most of the modern Rubella vaccines (including the combination vaccine MMR) contain the RA 27/3 strain, which was developed by Stanley Plotkin and Leonard Hayflick at the Wistar Institute in Philadelphia. The vaccine was attenuated and prepared in the WI-38 normal human diploid cell strain which was developed by Hayflick and provided to Plotkin by him. In order to isolate the virus, instead of taking swab samples from the throats of infected patients, which could have been contaminated with other resident viruses, Plotkin decided to utilize aborted fetuses provided by the department of Obstetrics and Gynecology of the Hospital of the University of Pennsylvania. At the time, abortion was illegal in most of the United States (including Pennsylvania), but doctors were allowed to perform "therapeutic abortions" when the life of the woman was in danger. Some started to perform them also on women infected with rubella. Several dozens of aborted fetuses were collected and studied by Plotkin. The kidney tissue from fetus 27 produced the strain that was used to develop the attenuated rubella vaccine. The name RA 27/3 refers to "Rubella Abortus", 27th fetus, 3rd organ to be harvested (the kidney). The vaccine was first approved by the UK in 1970. The strain became the preferred vaccine used by pharmaceutical companies over the HPV-77, due to several considerations, including its higher immunogenicity; Merck made it its mainstay rubella vaccine in 1979. Parkman and his team did not monetize their patents, wanting the vaccine to be freely available.

Commonly used automated secondary structure assignment programs, such as DSSP, suggest <1% of proteins contain a π-helix. This mis-characterization results from the fact that naturally occurring π-helices are typically short in length (7 to 10 residues) and are almost always associated with (i.e. flanked by) α-helices on either end. Nearly all π-helices are therefore cryptic in that the π-helical residues are incorrectly assigned as either α-helical or as "turns". Recently developed programs have been written to properly annotate π-helices in protein structures and they have found that 1 in 6 proteins (around 15%) do in fact contain at least one π-helical segment. Natural π-helices can easily be identified in a structure as a "bulge" within a longer α-helix. Such helical bulges have previously been referred to as α-aneurisms, α-bulges, π-bulges, wide-turns, looping outs and π-turns, but in fact are π-helices as determined by their repeating i + 5 → i hydrogen bonds. Evidence suggests that these bulges, or π-helices, are created by the insertion of a single additional amino acid into a pre-existing α-helix. Thus, α-helices and π-helices can be inter-converted by the insertion and deletion of a single amino acid. Given both the relatively high rate of occurrence of π-helices and their noted association with functional sites (i.e. active sites) of proteins, this ability to interconvert between α-helices and π-helices has been an important mechanism of altering and diversifying protein functionality over the course of evolution.

A common classroom demonstration involves holding a piece of paper horizontally so that it droops downward and then blowing over the top of it. As the demonstrator blows over the paper, the paper rises. It is then asserted that this is because "faster moving air has lower pressure". One problem with this explanation can be seen by blowing along the bottom of the paper: if the deflection was caused by faster moving air, then the paper should deflect downward; but the paper deflects upward regardless of whether the faster moving air is on the top or the bottom. Another problem is that when the air leaves the demonstrator's mouth it has the same pressure as the surrounding air; the air does not have lower pressure just because it is moving; in the demonstration, the static pressure of the air leaving the demonstrator's mouth is equal to the pressure of the surrounding air. A third problem is that it is false to make a connection between the flow on the two sides of the paper using Bernoulli's equation since the air above and below are different flow fields and Bernoulli's principle only applies within a flow field. A correct explanation of why the paper rises would observe that the plume follows the curve of the paper and that a curved streamline will develop a pressure gradient perpendicular to the direction of flow, with the lower pressure on the inside of the curve.

Sources: en.wikipedia.org

Further detail

During the mid-19th century, attempts were made to ship agricultural products by rail. As early as 1842, the Western Railroad of Massachusetts was reported in the June 15 edition of the Boston Traveler to be experimenting with innovative freight car designs capable of carrying all types of perishable goods without spoilage. The first refrigerated boxcar entered service in June 1851, on the Northern Railroad (New York) (or NRNY, which later became part of the Rutland Railroad). This "icebox on wheels" was a limited success since it was only functional in cold weather. That same year, the Ogdensburg and Lake Champlain Railroad (O&LC) began shipping butter to Boston in purpose-built freight cars, using ice for cooling.

=== Chemical modification === Soluble fragments of graphene can be prepared in the laboratory through chemical modification of graphite. First, microcrystalline graphite is treated with an acidic mixture of sulfuric acid and nitric acid. A series of oxidation and exfoliation steps produce small graphene plates with carboxyl groups at their edges. These are converted to acid chloride groups by treatment with thionyl chloride; next, they are converted to the corresponding graphene amide via treatment with octadecyl amine. The resulting material (circular graphene layers of 5.3 Å or 5.3×10−10 m thickness) is soluble in tetrahydrofuran, tetrachloromethane and dichloroethane. Refluxing single-layer graphene oxide (SLGO) in solvents leads to size reduction and folding of individual sheets as well as loss of carboxylic group functionality, by up to 20%, indicating thermal instabilities of SLGO sheets dependent on their preparation methodology. When using thionyl chloride, acyl chloride groups result, which can then form aliphatic and aromatic amides with a reactivity conversion of around 70–80%.

=== Macular degeneration === Overexpression of VEGF causes increased permeability in blood vessels in addition to stimulating angiogenesis. In wet macular degeneration, VEGF causes proliferation of capillaries into the retina. Since the increase in angiogenesis also causes edema, blood and other retinal fluids leak into the retina, causing loss of vision. Anti-angiogenic drugs targeting the VEGF pathways are now used successfully to treat this type of macular degeneration

=== Sale to Sidney Feltenstein; Grotech subsidiary === In December 1994, Taubman sold A&W to Sidney Feltenstein, with the aim of pushing the chain's international expansion further, while still maintaining its headquarters in Livonia. At the time, there were 790 restaurants (688 in the United States and 102 abroad), with the bulk of the international locations located in Malaysia, Thailand and Japan, as well as in Mexico and the United Arab Emirates. Earlier in 1994, its hundredth international location opened at a tourist attraction in Bangkok: a crocodile farm. In January 1995, operations were taken over by Grotech Capital Partners, for a sum of $20 million, with Feltenstein as the chain's new CEO. An agreement was signed in 1996 with Walmart to provide restaurants in seven locations. The menu would add items depending on the region, with the rest being its standard fare. That year, its restaurants were renovated to feature an aesthetic referred to by Feltenstein as "contemporary nostalgia". The move mirrored that of Dairy Queen, which had also opened a test location with a similar feel. A&W also operated restaurants in Monterrey, a key city in northern Mexico. In 1997, A&W acquired Carousel Snack Bars, including its 175 units in malls. The agreement made the chain the owner of these units, while continuing to franchise restaurants.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is melanotan II?

It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.

Does it require ultraviolet light to work?

Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.

Why is receptor selectivity discussed so often?

Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

Network